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Ion channels are essential in a wide range of cellular functions and their malfunction under-
lies many disease states making them important targets in drug discovery. The availability
of standardized cell lines expressing ion channels of interest lead to the development of
diverse automated patch clamp (APC) systems with high-throughput capabilities. These
systems are now available for drug screening, but there are limitations in the application
range. However, further development of existing devices and introduction of new systems
widen the range of possible experiments and increase throughput. The addition of well
controlled and fast solution exchange, temperature control and the availability of the cur-
rent clamp mode are required to analyze standard cell lines and excitable cells such as
stem cell-derived cardiomyocytes in a more physiologically relevant environment. Here we
describe two systems with different areas of applications that meet the needs of drug
discovery researchers and basic researchers alike. The here utilized medium throughput
APC device is a planar patch clamp system capable of recording up to eight cells simultane-
ously. Features such as temperature control and recordings in the current clamp mode are
described here. Standard cell lines and excitable cells such as stem cell-derived cardiomy-
ocytes have been used in the voltage clamp and current clamp modes with the view to
ﬁnding new drug candidates and safety testing methods in a more physiologically relevant
environment. The high-throughput system used here is a planar patch clamp screening
platform capable of recording from 96 cells in parallel and offers a throughput of 5000 data
points per day. Full dose response curves can be acquired from individual cells reducing
the cost per data point.The data provided reveals the suitability and relevance of both APC
platforms for drug discovery, ion channel research, and safety testing.
Keywords: automated patch clamp, electrophysiology, temperature control,TRPV3, hERG, nAChR, current clamp,
ion channels
INTRODUCTION
Ion channels are pore-forming proteins that catalyze the pas-
sive transport of ions through biological membranes. Given the
importance of ion channels in many physiological processes, it is
no surprise that they are a major therapeutic target (Hille, 1992;
Ashcroft, 2000). To date over 13% of currently known drugs have
been shown to act primarily on ion channels, a multi-billion dollar
industry (Clare, 2010).
Patch clamp electrophysiology remains the gold standard for
studying ion channels since it was ﬁrst described in the 1970s
(Neher and Sakmann, 1976). However, conventional patch clamp
is notoriously low throughput and technically demanding. Thus,
automation of the patch clamp technique increases throughput
and ease of use (Farre et al., 2009), bringing patch clamp to a
wider audience.
Over the last decade, several automated patch clamp (APC)
devices became available and are now commonplace in many lab-
oratories (for recent reviews see Dunlop et al., 2008; Farre et al.,
2008). These devices provide information rich data whilst increas-
ing throughput, which is essential for both drug discovery and
safety testing. Such APC devices are not limited to the phar-
maceutical industry. Universities and research institutions have
also started to implement the use of higher throughput APC
devices in their laboratories (Milligan et al., 2009; Balansa et al.,
2010). National screening centers and high-throughput core facil-
ities are appearing worldwide, combining increased throughput,
sophistication, and high quality.
However, the providers of APC devices are pushing the bound-
aries by continually improving existing platforms and creating
new and innovative devices, which have higher throughput and
new features. Such features are introduced in this paper.
MATERIALS AND METHODS
SYSTEM COMPONENTS
The medium throughput patch clamp device used here was a
Patchliner System (Nanion Technologies, Germany). It includes
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four (Patchliner Quattro) or eight (Patchliner Octo) ampliﬁer
channels (EPC-10 Quadro ampliﬁers, HEKA Elektronik, Ger-
many), PatchControlHT software, integrated with PatchMaster
(HEKA Elektronik, Germany), for acquisition of data, and online
analysis of the recorded data. The data analysis software for visu-
alization of traces and results of data analysis is IGOR Pro-based
(WaveMetrics, USA). The data output and compound informa-
tion is compatible with most database formats. A graphical user
interface is used to program and execute up to 48 unattended
recordings, approximately 500 data points per day can be gener-
ated. User intervention is possible at any time during an experi-
ment. The software offers a detailed user control in combination
with versatile experimental possibilities. In comparison to other
available APC devices the Patchliner is equipped with temperature
control, continuous waste removal allowing an unlimited number
of compound additions, and the ability to perform current clamp
recordings.
The high-throughput system utilized here was the SyncroPatch
96 (Nanion Technologies, Germany), a screening platform capa-
ble of recording from 96 cells in parallel. Full dose response
curves can be acquired from individual cells with giga-ohm (GΩ)
seals, generation of up 5000 data points per day is possible. The
platform has built-in ampliﬁers (Triton+, Tecella LLC, USA),
its own dedicated software (PatchControl96, Nanion Technolo-
gies, Germany), and a data analysis package. Temperature con-
trol or current clamp are not integrated features. Data output
and compound information is compatible with most database
formats.
For both systems, planar borosilicate-glass patch clamp chips
are used (Farre et al., 2009).
CELL CULTURE FOR PLANAR PATCH CLAMP
For planar patch clamp, a wide range of different cell suspensions
can be used (Bruggemann et al., 2008; Li et al., 2008; Milligan
et al., 2009). Cell suspensions for APC devices utilizing planar
patch clamp chips should be homogeneous (Milligan et al., 2009),
since the cell capture is blind. The cells are ideally single. Cell clus-
ters, cell fragments, or debris in the suspension decrease the cell
capture rate and, thus, the overall success rate.
Standard cell lines
The conﬂuency of the cells should be in the range of 50–80%. For
culturing cells for use on the Patchliner and SyncroPatch 96, T75
ﬂasks are typically used. For harvesting the cells for patch clamp
experiments, no signiﬁcant difference in percentage of giga-ohm
seals could be found for using Trypsin, accutase, or phosphate-
buffered saline ethylenediaminetetraacetic acid (PBS–EDTA) for
lifting the cells.
Cell lines used in this paper:
hERG stably expressed in HEK cells (Millipore, USA).
hTRPV3 stably expressed in HEK cells (Millipore, USA).
hNav1.5 stably expressed in HEK cells (Millipore, USA).
P2X2/3 receptors stably expressed in 1321N1 cells (Evotec,
Germany).
HEK cells stably expressing homomeric human nAChR α7
subunits (Galantos Pharma GmbH, Germany).
GABAA subunits α1β2γ2 stably expressed in HEK cells (source
anonymous).
Harvesting protocol for cell lines. Amounts are listed for a T75
ﬂask exemplarily:
• Wash twice with 10 ml PBS (without Ca2+ and Mg2+).
• Add 2 ml of detacher (PBS–EDTA 2 mM, Trypsin/EDTA, Accu-
tase etc.).
• Incubate approximately 3 min in a humidiﬁed incubator at 37˚C
and 95% O2/5% CO2.
• Check the detachment of cells using a microscope. Move the
plate or ﬂask gently to detach all cells from the bottom (do not
hit the ﬂask, tap gently if necessary).
• Add 10 ml of cell culture medium (room temperature, RT),
according to the cells used.
• Pipette the cells gently up and down with a 10-ml pipette.
• After pipetting ﬁve times, look at the cells under a microscope.
If the cells are single ( 80–90%), no further pipetting is needed.
• If cells still form clusters, gently pipette cells another 10 times.
Repeat this step until cells are single ( 80–90%).
• Centrifuge the cells (2 min, 100 g).
• Discard the supernatant.
• Resuspend the cells in external recording solution resulting in a
cell density of approximately 1× 106 cells/ml.
• A visual control of the cell suspension under the microscope
should reveal single, round cells with smooth membrane edges
and few cell clusters.
• Transfer cells to the cell hotel of the Patchliner where cells are
continuously pipetted up and down to maintain single cells and
viability.
Stem cell-derived cardiomyocytes
Differentiation of genetically modiﬁed mouse embryonic stem
cells (mESC) and the antibiotic selection of the mESC-derived
cardiomyocytes have been described previously in detail (Kolossov
et al., 2006).
Vials of at least one or ﬁve million viable mESC-derived
cardiomyocytes (Cor.At cells, Lonza, Walkersville, USA, cata-
log numbers XCAC-1010 or XCAC-1050, respectively) obtained
directly from the manufacturer (Axiogenesis, Cologne, Germany)
were thawed as described in the distributors technical man-
ual (https://www.lonza.com/go/literature/). For long-term stor-
age, the cells are frozen as single cell suspensions in liquid nitrogen
or −150˚C freezers. When cultured overnight at an appropriate
cell density, the thawed cardiomyocytes form spontaneously and
synchronously contracting monolayers.
Cells were seeded at a density of 105 viable cells/cm2 culture
area in one T25 cell culture ﬂask with 5 ml Cor.At Complete
Culture Medium when a vial with one million viable mESC-
derived cardiomyocytes was used. Two T75 cell culture ﬂasks each
with 10 ml Cor.At Complete Culture Medium were used when
a vial containing ﬁve million mESC-derived cardiomyocytes was
taken.
iCell cardiomyocytes (Cellular Dynamics International, Madi-
son, WI, USA) were plated on T25 culture ﬂasks coated
with 0.1% gelatin as per manufacturers’ instructions. A vial
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containing> 1.5× 106 platable cells (catalog number CMC-100-
110-001)was plated ononeT25ﬂask, a vial containing> 7.5× 106
platable cells (catalog number CMC-100-110-005) was plated
on ﬁve T25 ﬂasks. For each 1× 106 viable cells, 9 ml cold iCell
Cardiomyocytes Plating Media (4˚C) was used. After 24 h the
media was exchanged for iCell Cardiomyocytes Maintenance
Media.
Harvesting protocol for mouse stem cell-derived Cor.At car-
diomyocytes. Amounts are listed for a T75 ﬂask exemplarily:
• Cells must be cultured for at least 2–4 days before patch clamp
experiments are performed.
• Wash twicewith 10 ml 4˚CcoldPBS (withoutCa2+/Mg2+)/EDTA
(2 mM).
• Incubate at 4˚C for 15 min.
• Remove PBS/EDTA.
• Add 5 ml pre-warmed (RT) Trypsin 0.05%/EDTA 0.02% in PBS
solution.
• Incubate 4–5 min in a humidiﬁed incubator at 37˚C and 95%
O2/5% CO2.
• Check the detachment of cells under a microscope. Move the
plate or ﬂask gently to detach all cells from the bottom (do not
hit the ﬂask).
• Add 10 ml of Cor.At Complete Culture Medium (RT).
• Centrifuge the cells (2 min, 100 g).
• Discard the supernatant.
• Add external recording solution resulting in a cell density of
approximately 1× 106- 5× 107/ml. Carefully resuspend the
cells by gentle pipetting (two times max.).
• A visual control of the cell suspension under the microscope
should reveal single, round cells with smooth membrane edges
and no cell clusters.
• Transfer cells to the cell hotel of the Patchliner where cells are
continuously pipetted up and down to maintain single cells and
viability.
Harvesting protocol for human iPS cell-derived iCell cardiomy-
ocytes. Amounts are listed for a T25 ﬂask exemplarily:
• Cells should be cultured for at least 2–4 days before patch clamp
experiments are performed.
• Wash twicewith 5 ml 4˚CcoldPBS (withoutCa2+/Mg2+)/EDTA
(2 mM).
• Add 5 ml 4˚C cold PBS (without Ca2+/Mg2+)/EDTA (2 mM).
• Incubate at 4˚C for 15 min.
• Remove PBS/EDTA.
• Add 2 ml Trypsin 0.05%/EDTA 0.02% in PBS solution.
• Rock the dish from side to side to ensure an even distribution
of Trypsin.
• Immediately remove the Trypsin (before cells start to detach).
Despite removing the liquid, there is still enough Trypsin on the
surface to detach the cells.
• Incubate the ﬂask for 3–8 min at 37˚C and 95% O2/5% CO2.
Check the detachment of cells under a microscope after 3 min.
Move the plate or ﬂask gently to detach all cells from the bot-
tom (do not hit the ﬂask, tap gently if required). If cells are not
detached return the ﬂask to the incubator.
• Once cells start to detach, add 1 ml media and 1 ml exter-
nal recording solution. Carefully resuspend the cells by gentle
pipetting (two times max.).
• Transfer cells to the cell hotel of the Patchliner where cells are
continuously pipetted up and down to maintain single cells and
viability.
Patch clamp solutions. Internal solution: 50 mM KCl, 10 mM
NaCl, 60 mM KF, 20 mM EGTA, 10 mM HEPES/KOH, pH 7.2 (for
Figures 1, 2, 5, 6, and 8) or 50 mM CsCl, 10 mM NaCl, 60 mM
FIGURE 1 | Effect of erythromycin on hERG-mediated currents at (A)
room temperature and (B) 35˚C.The graphs are shown on the same scale.
Hundred micromolar erythromycin signiﬁcantly blocked hERG currents at
35˚C but had little effect on hERG currents at RT, n =1 each.
FIGURE 2 | Concentration response curves for erythromycin at room
temperature (n=12) and at 35˚C (n=18). Erythromycin is approximately
10-fold more potent at 35˚C compared with room temperature. An overlay
of the concentration response curves at room temperature and 35˚C clearly
shows the shift in potency.
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FIGURE 3 | (A) Currents elicited using a voltage ramp protocol from −100
to 100mV over 200ms and activation of TRPV3 receptors by increasing
concentrations of 2-APB. (B) Concentration response curve for n =11 cells
revealing an EC50 for 2-APB of 61.1±7.6μM.
FIGURE 4 | Current traces ofTRPV3 activated by heated solution.
External solution was heated to the temperature shown and applied to the
cell. Currents started to activate at ≥38˚C.
CsF, 20 mM EGTA, 10 mM HEPES/CsOH (for Figures 3, 4, 9, and
10). External solution (except for recordings shown in Figure 9B):
140 mM NaCl, 4 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 5 mM d-
Glucose monohydrate, 10 mM HEPES/NaOH pH 7.4. External
solution for nicotinic α7 channel recordings (Figure 9B): 80 mM
NaCl, 3 mM KCl, 45 mM CaCl2, 10 mM HEPES (Na+ salt)/HCl,
pH 7.4. Solutions for action potential (AP) recording in the con-
ventional patch clamp rig (Figure 5G) were 130 mM KAs, 15 mM
KCl, 5.5 mM MgCl2, 5 mM Na2ATP, 5 mM K2 phosphocreatine,
10 mM HEPES, pH 7.25 (internal) and 140 mM NaCl, 4 mM KCl,
2 mM CaCl2, 1 mM MgCl2, 10 mM glucose, 10 mM HEPES, pH
7.35 (external).
Electrophysiology. Whole cell patch clamp recordings were con-
ducted as previously described (Farre et al., 2009; Stoelzle et al.,
2011). Currents were elicited using voltage protocols in the voltage
clamp mode. For hERG, a voltage step protocol from the holding
potential (−80 mV) to +40 mV for 500 ms followed by a 500-ms
step to −40 mV, repeated every 20 s. Peak amplitude at −40 mV
was used for analysis. For Nav 1.5, currents were elicited using
10 ms voltage steps from −120 to 0 mV repeated every 1 s. For
ligand-gated experiments, cells were held at a constant holding
potential of −80 mV and solutions were exchanged within 100 ms
to activate receptors and minimize ligand exposure time. For heat
activation of TRPV3 channels, external solution was heated to the
temperature indicated and applied to the cell. Alternatively, 2-APB
at increasing concentrations at RT was used to activate TRPV3. A
voltage ramp protocol from −100 to 100 mV over 200 ms was used
to record TRPV3 currents. Current amplitude at 90 mV was used
for analysis. APs were generated using a depolarizing pulse to the
threshold at which an AP was elicited. Membrane potential was
kept at −80 to −100 mV (cell dependent). The AP traces shown
represent an average response of four recorded APs. The APs were
normalized to the time point of the beginning of the upstroke.
Equipment: NPC-16 Patchliner Octo (with temperature control
option) and SyncroPatch 96 (Nanion Technologies GmbH, Ger-
many). Patch clamp ampliﬁer for the Patchliner: EPC-10 Quadro
(HEKA Elektronik GmbH, Germany), patch clamp ampliﬁer for
the SyncroPatch 96: Triton+ (Tecella, CA, USA), PatchControl
HT and PatchControl 96 software (Nanion Technologies GmbH,
Germany). Software for data acquisition (PatchMaster, HEKA
Elektronik GmbH, Germany; PatchControl 96, Nanion Technolo-
gies GmbH, Germany) and analysis (IGOR Pro WaveMetrics Inc.,
OR, USA and SyncroPatch Data Analysis Package, Nanion Tech-
nologies GmbH,Germany). NPC-16 or NPC-96 chips (single-use,
disposable; Nanion Technologies GmbH, Germany) were used.
APPLICATIONS AND NOVEL FEATURES
TEMPERATURE REGULATION
Experiments at physiological temperature
Compounds can display different properties or different poten-
cies at physiological temperature (35˚C) vs. RT. Therefore, it is
a desirable option to be able to study ion channels at elevated
temperature. To meet this need, several heating elements were
introduced into the Patchliner. The surrounding of the planar
patch clamp chip can be heated to maintain constant, physiolog-
ical temperature. The solution, which is pipetted onto the cell,
can also be heated separately. To prevent any degradation of com-
pounds inside the pipette due to long heating phases, only the
volume which is required (typically 40–100 μl, depending on the
application) is heated, directly before application to the chamber
of the patch clamp chip. Heating of the solution, which is applied
to the cell takes 23.4± 4 s (for temperatures between 30 and 70˚C;
data not shown).
One compound, which has been shown to have an increase
in potency at physiological temperature, is erythromycin.
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FIGURE 5 | (A) Representative traces of a Cor.At cardiomyocyte recorded
in the voltage clamp mode and block by increasing concentrations of TTX.
Raw data of Na+ currents in control solution and in the presence of
increasingTTX concentrations (0.3, 1, 3, 10, and 30μM), elicited by 10ms
voltage steps to 0mV from a holding potential of −80mV, sweep interval
2 s. (B) Corresponding concentration response curve with a calculated IC50
of 1.3±0.4μM (n =3). (C) Corresponding time plot of the experiment
showing the stability of the recording. Current amplitude was reduced
step by step upon application of the increasing concentrations. A washout
of TTX was performed at the end of experiment. (D) Representative traces
of highly reproducible APs as recorded in the current clamp mode. Sweep
interval between each stimulus was 10 s. Traces were recorded over
15min, the ﬁrst and the last 4 APs are shown. The same experiment as
shown in (A) was performed on the semi-automated patch clamp system
Port-a-Patch (E). The corresponding IC50 was calculated to be 1.1±0.5μM
(n =4) (F). (G) Comparison of an AP recorded with the Port-a-Patch (top
trace) and using a conventional patch clamp rig (lower trace). Gray line
indicates 0mV.
Erythromycin is a macrolide antibiotic, which can cause QT
prolongation and cardiac arrhythmia. Erythromycin has been
shown to block hERG channels at physiological temperature with
an IC50 of approximately 40 μM (Stanat et al., 2003). How-
ever, at RT erythromycin is much less potent. At a concentration
of 100μM, erythromycin causes no signiﬁcant block of hERG
currents at RT but signiﬁcantly blocks currents at physiological
temperature (Guo et al., 2005).
Here we present data collected on a Patchliner Octo with tem-
perature control at RT and at 35˚C and the effect this has on
the potency of erythromycin. Current responses of two individual
cells to 500 ms voltage pulses to +40 mV and then −40 mV in the
presence and absence of 100μM erythromycin at RT and 35˚C
are shown in Figure 1. At RT (Figure 1A) 100μM erythromycin
caused little reduction in current amplitude (at −40 mV; approx.
15%) compared with an almost 50% reduction in current ampli-
tude at 35˚C (Figure 1B). This is in good agreement with the
literature (Guo et al., 2005).
Typically, single concentrations of erythromycin were applied
to each cell. Figure 2 shows averaged concentration response
curves for erythromycin at RT and at 35˚C overlaid. At higher
concentrations (300μM), erythromycin did block hERG currents
at RT by approximately 40% and gave an IC50 of 427.5 μM calcu-
lated from the graph (n = 12). At 300μM, erythromycin blocked
hERG currents at 35˚C by 70% and the IC50 at this tempera-
ture was calculated to be 30.7μM (n = 18). This is in excellent
agreement with values reported in the literature (Stanat et al.,
2003).
Table 1 shows success rates of reaching a giga-ohm seal and
cell parameters for hERG stably expressed in HEK cells (Millipore,
USA), n = 35.
Heat activation of TRPV3
Transient receptor potential (TRP) channels are an important class
of receptors found widely distributed throughout the mammalian
central and peripheral nervous systems. They have been shown
to be activated by many stimuli including temperature, mechano-
stimulation, divalent cations, and pH (for review see Clapham,
2003). TRP channels are receiving much attention as potential
targets for the treatment of, for example, chronic pain, asthma,
anddiabetes insipidus (Clapham,2003;GudermannandFlockerzi,
2005).
We have used the Patchliner to study TRPV3 channels using
either 2-APB or heat to activate the receptors. High quality data
could be achieved with a high success rate for obtaining seals in
the GΩ range (> 80%). Table 2 shows success rates and cell para-
meters for TRPV3 stably expressed in HEK cells (Millipore, USA)
activated by either 2-APB or heat.
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FIGURE 6 | (A) Raw data of Na+ currents of one human iPS cell-derived
iCell cardiomyocyte in control solution and in the presence of increasing
TTX concentrations (0.3, 1, 3, 10, and 30μM). (B) Corresponding
concentration response curve for an average of four cells reveals an IC50 of
2.5±1.0μM for TTX (n =4). (C) In the current clamp mode, a TTX
concentration-dependent reduction of the amplitude as well as a
concentration-dependent AP shortening was observed. The IC50 was
calculated to be 5.6μM (n =2).
TRPV3 currents were activated by 2-APB in a concentration-
dependent manner. Figure 3 shows current traces of TRPV3
expressed inHEKcells and activationby2-APB.The concentration
response curve is also shown revealing an EC50 = 61.1± 7.6μM
(n = 11). This is in good agreement with values reported in the
literature (Chung et al., 2004; Hu et al., 2009).
TRPV3 receptors can also be activated by temperature. Figure 4
shows the activation of TRPV3 channels by increasing tempera-
ture. To do these experiments, external bath solution was heated
in the robotic pipette and after the set temperature was reached,
FIGURE 7 |The SyncroPatch 96 is an automated patch clamp device for
parallel recordings and online analysis of up to 96 cells. All 96 cells are
voltage clamped at any time. The pipette arm contains 16 channels,
therefore 16 of the cells are served with solution in parallel. The device
utilizes planar borosilicate-glass chips. The solution exchange for the
individual cell is in the range of 100ms.
FIGURE 8 | Development of seal stability of 96 Nav1.5 overexpressing
HEK cells over time on the SyncroPatch 96. 69.8% of the cells had a
stable membrane resistance of >500MΩ (783±29MΩ) for 20min, 67.7%
of the cells were stable until the experiment was ﬁnished after 30min.
43.8% of cells having a membrane resistance of >1GΩ (1865±99MΩ)
were stable for 20min, 31.3% of them still had a stable resistance after
30min. Note the increase of cell percentage developing a higher resistance
within 10min after reaching the whole cell conﬁguration.
the heated solution was applied to the cell at a speed of 10μl/s.
Outwardly rectifying currents started to activate at 38˚C and
increased in amplitude as temperature increased, up to 54˚C, in
good agreement with the literature (Peier et al., 2002; Smith et al.,
2002; Xu et al., 2002).
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FIGURE 9 | Multiple compound additions can be performed,
allowing the generation of full concentration response curves on
individual cells. (A) P2X2/3 receptors expressed in a 1321N1 cell were
repeatedly activated by 10μM ATP (three times activation with
intermittent wash steps; data courtesy of Evotec AG). (B) Activation of
nicotinic α7 receptors with 30, 100, and 300μM Ach in one cell. Cells
stably expressing human nAChRs were kindly provided by Galantos
Pharma GmbH.
FIGURE 10 | (A) Graphical user interface for software used on a Patchliner
system. PatchMaster raw data ﬁles from eight parallel recordings of Nav1.5
expressing HEK cells. A screenshot of the oscilloscope with current traces
and online analysis windows with corresponding current–voltage relations are
shown. Data are loaded into IGOR Pro (B) with aid of a macro. After a few
mouse clicks, individual IC50 values for a compound (here lidocaine) from each
cell and the averaged data, including all relevant values and calculations, are
displayed.
PARALLEL CURRENT CLAMP MEASUREMENTS
The Patchliner was used in combination with stem cell-derived
cardiomyocytes, a standardized and pure cardiac myocyte model.
This is a new opportunity because cardiac toxicity can now be
evaluated in a cell type which better represents the real physi-
ological environment compared with a cell line overexpressing
a particular ion channel. Patch clamp measurements with car-
diac myocytes are sophisticated experiments that were, until now,
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only possible using conventional patch clamp using freshly iso-
lated cardiac myocytes from animals. Stem cell-derived cardiac
myocytes are commercially available, a pure population and ready-
to-use resulting in a quicker cell preparation time and better
reproducibility of the assay.
The Patchliner was used for pharmacological experiments in
both voltage clamp and current clamp modes so that the effects
of cardiotoxic compounds could be directly investigated on both
ion currents and APs. The eight-channel system Patchliner and
the one-channel system Port-a-Patch (Farre et al., 2007) are the
currently only APC devices which allow for both voltage and cur-
rent clamp recordings. We used mouse stem cell-derived Cor.At
cardiomyocytes and human iPS cell-derived iCell cardiomyocytes.
The cells showed expression of Na+, Ca2+, and K+ channels in the
voltage clamp mode after a minimum of 2 days of culturing (for
Cor.At cells, see also Stoelzle et al., 2011). Cor.At cardiomyocytes
which had been in culture for more than 4 days required a pro-
longed incubation with the digestion enzyme to obtain single cell
suspensions. This in turn reduced the success rates to obtain giga-
ohm seals, hence we used cells that were in culture for 2–4 days.
We did not see a difference between those cells with regards to
channel expression or success rate.
After optimization of the harvesting methods, the Cor.At and
iCell cardiomyocytes had a high success rate when used on the
Patchliner,which resulted in long lasting recordings both in voltage
clamp and current clamp modes (Figures 5 and 6). A typical phar-
macological experiment in the voltage clamp mode using multiple
concentrations of a compound (in this case TTX) and washout to
check reversibility was performed with a Patchliner (Figures 5A–C
and 6) and also with the Port-a-Patch (Figures 5E,F). In the
current clamp mode, APs were elicited by a short depolarizing
pulse (1 ms current injection to the threshold at which an AP
was elicited). The shape was not only comparable to the shape
of APs recorded with the one-cell-at-a-time system Port-a-Patch
and a conventional patch clamp rig (Figure 5G), but also sta-
ble over a long period of time (Figure 5D), conﬁrming that the
cells are suitable for analyzing compound effects on APs. There-
fore the generation of a full concentration response curve on an
individual cell can be generated easily due to the stability of the
measurements (Figure 5D; see also Stoelzle et al., 2011). Phar-
macological experiments on APs have been extensively studied on
Cor.At cells, including a study on frequency dependent inhibi-
tion of Na+ channels (Stoelzle et al., 2011). Figure 6C shows APs
generated using iCell cardiomyocytes using a short depolarizing
pulse (as described above) and the expected shortening of the AP
duration and a slowing of velocity of the upstroke by increasing
concentrations of TTX. The IC50 achieved in the current clamp
mode [IC50 = 5.6μM (n = 2)] agrees well with the IC50 from volt-
age clamp [2.5± 0.9μM (n = 4)]. Table 3 shows success rate and
cell parameters for iCell cardiomyocytes (n = 69).
HIGH-THROUGHPUT AUTOMATED PATCH CLAMP
The SyncroPatch 96 (Figure 7) is a screening platform which
generates high quality patch clamp data and provides accurate
pharmacology because full dose response curves can be acquired
from individual cells with giga-ohm seals. It is a well suited tool for
secondary screening efforts and for safety testing either for dose
Table 1 | Success rate, cell parameters, and experiment duration for
n =35 HEK cells stably expressing hERG.
Success rate (%) Rmemb (GΩ) Cm (pF) Rs (MΩ) Exp. duration
(min)
65 2.4±0.5 7.9±1 7.0±1 19±2
Parameters of cells recorded at RT and 35˚C were pooled since no difference
was observed between those conditions. Given errors are standard errors of the
mean. Sixty-ﬁve percent of the cells had a membrane resistance of 2.4±0.5GΩ;
the seals were stable over 19±2min.
Table 2 | Success rate, cell parameters, and experiment duration for
n =87 HEK cells stably expressingTRPV3.
Success rate (%) Rmemb (MΩ) Cm (pF) Rs (MΩ) Exp. duration
(min)
81 934±191 18±1 6.2±0.4 39±2
Given errors are standard errors of the mean. Eighty-one percent of the cells had
a membrane resistance of 934±191MΩ, the seals were stable over 39±2min.
Table 3 | Success rate, cell parameters, and experiment duration for
n =69 iCell cardiomyocytes.
Success rate (%) Rmemb (GΩ) Cm (pF) Rs (MΩ) Exp. duration
(min)
46 1.4±0.3 12.9±1 6.0±0.6 18.2±1
Given errors are standard errors of the mean. Forty-six percent of the cells had a
membrane resistance of 1.4±0.3GΩ, the seals were stable over 18.2±1min.
Table 4 | In total, 64 of the 96 cells reached a seal resistance of around
1.8GΩ within the first 10min after reaching the whole cell mode, 21
cells reached a resistance of around 783MΩ.
Number
of cells
Rmemb
(MΩ)
Number of cells stable
for 20min (%)
Number of cells stable
for 30min (%)
64 1865±99 43.8 31.3
21 783±29 69.8 67.7
11 152±48 n.a. n.a.
The remaining cells had a resistance of around 152MΩ. 43.8% of the cells hav-
ing a giga-ohm seal remained their seal for 20min, 31.3% had the giga-ohm seal
still after 30min. 69.8% of the cells having around 783MΩ as a seal resistance
remained their seal for 20min, 67.7% for 30min. N=96 cells, recorded on one
NPC-96 patch clamp chip, given errors are standard errors of the mean.
response analysis or single-point screening. Table 4 shows success
rates of representative experiments using Nav1.5 overexpressing
HEK cells on one patch clamp chip (NPC-96 patch clamp chip
for 96 cells being recorded in parallel). Furthermore, the stability
of cells over time is listed as well. Figure 8 shows a correspond-
ing graphical depiction of the development of the seal stability
over time.
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Voltage clamp recordings are continuous during compound
application and solution exchange time is in the order of 100 ms.
This allows for screening of compound action on ligand- and
voltage-gated ion channels. An APC device with fast solution
exchange is a prerequisite for studying fast desensitizing chan-
nels such as nicotinic acetylcholine receptor (nAChR). Enhancers
of nAChRs, such as galantamine, may have therapeutic beneﬁt
for Alzheimer’s disease (Samochocki et al., 2003). It is, therefore,
essential to be able to search for nAChR agonists and enhancers at
a higher throughput.
Figure 9A shows a typical screenshot with recordings of a
ligand-gated ion channel, P2X2/3. P2X2/3 receptors in a 1321N1
cell were repeatedly activated by 10μM ATP, demonstrating the
reliability of repetitive drug applications. nAChR α7 express-
ing HEK cells were activated by increasing concentrations of
ACh (30, 100, 300μM; Figure 9B). Given the importance of
this channel as a potential therapeutic target for conditions
such as Alzheimer’s disease, schizophrenia, and Parkinson’s dis-
ease (for review see Colquhoun et al., 2003; Albuquerque et al.,
2009), it is critical that researchers have tools to study them
reliably.
The disposable planar borosilicate-glass substrate used for seal
formation ensures high quality data and long lasting seals when
using the Patchliner and SyncroPatch 96. In general, with a suc-
cess rate for completed experiments of 51.7 ± 10% (n = 567), the
SyncroPatch 96 has a data throughput of approximately 5000 data
point per day. With a Patchliner Octo, having a success rate of
around 80%, approximately 500 data points can be generated per
day (Farre et al., 2009).
DATA ANALYSIS
Increasing the throughput in APC devices results in an increase
in data generation and, thereby, necessitates the need for auto-
mated data analysis. Figure 10A shows a screenshot of one run
on a Patchliner Octo, which records from eight cells at a time.
Here, Nav1.5 stably expressing HEK cells were used (Millipore,
USA). The raw data are saved as PatchMaster (.dat) ﬁles and an
additional Microsoft ofﬁce excel spreadsheet is generated, which
can be easily loaded in IGOR Pro (WaveMetrics, USA). We devel-
oped a macro which is implemented in IGOR Pro that enables the
upload, graphical display of raw data traces and IC50 calculation
of individual cells or an average of all cells for each compound in
summary (Figure 10B).
For the analysis of concentration response curves, the Syn-
croPatch 96 software provides an intuitive graphical user interface
(Figure 11). The recording sites are color coded according to user
deﬁned success criteria (membrane resistance, access resistance,
current amplitude etc.). The user can generate individual IC50
values or an average IC50 of the recorded cells. Current–voltage
relationships, leak-subtraction, and time-dependence of recorded
values can be displayed besides a repertory of other calculations.
DISCUSSION AND OUTLOOK
The APC devices used here for data recordings are equipped for
studying ion channels in various areas of research, drug discov-
ery, and safety screening. The data quality and reproducibility of
pharmacological experiments is consistent between the automated
systems and a manual patch clamp rig or semi-automated patch
clamp system like the Port-a-Patch as shown for current clamp
FIGURE 11 | Graphical user interface of the screening and data analysis
software used on the SyncroPatch 96. (A) Screenshot of depiction of raw
data of GABAA subunits α1β2γ2 expressing HEK cells as recorded on one
NPC-96 patch clamp chip. Ninety-six small color coded pictures as seen in
the upper left part display all 96 parallel recordings. Depending on the seal
resistance, pictures are green (Rmemb >100MΩ), blue (Rmemb =50–100MΩ),
light blue or gray (Rmemb <50MΩ or no cell capture). One highlighted
experiment is displayed below, 16 other selected experiments are displayed
on the right. Traces show currents of individual cells which were activated by
six GABA concentrations (0.3, 1, 3, 10, 30, and 100μM). Intermittent wash
steps with control solution were performed. (B) Screenshot showing the
same experiment as in (A), but displaying individual concentration response
curves. For highlighted experiments (in lower part and right), note the
different shades of blue overlaid on the curves, representing the six
increasing concentrations of GABA. The white color represents the
intermittent wash steps. (C) Averaged concentration response curve and
related parameters of successful experiments (here 70 out of 96) of the
same experiment.
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recordings from pluripotent stem cell-derived cardiomyocytes.
The overall instrument performance, success rates, longevity of
recordings, and compatibility with various cell lines and assay
types are fundamental for effective screening work in electrophys-
iology departments. Effective screening in the broader sense also
means cost effectiveness, which is, of course, an essential quali-
ﬁcation. The combination of an in vitro cardiac cell model with
higher throughput patch clamp screening technology opens up a
new way for cardiotoxicity prediction in a physiologically relevant
cell system. The ability to perform current clamp recordings and
a temperature-regulated cell environment are unique features of
the Patchliner, currently not available on other higher throughput
APC systems. Furthermore, the temperature control feature of the
Patchliner can be used to record ion currents andAPs at physiolog-
ical temperatures and to activate temperature-regulated receptors
such as the TRP family of receptors to discover speciﬁc inhibitors
with a reduced side-effect proﬁle. The data shown on TRP chan-
nels prove not only the versatility of the liquid handling that is
needed to repeatedly activate the cell by perfusing heated solution,
but also the exactness of heating and precisely timed exposure of
the cell to the heated solution.
The Patchliner is compatible with many different cell lines,
showing little discrepancy between the cell lines used (data
described in this paper and Bruggemann et al., 2006; Farre et al.,
2007, 2009). Interestingly, recordings of a variety of primary cells
have also been described using the Patchliner (Milligan et al.,
2009). Few, if any,otherAPCdevices have been able todemonstrate
such compatibility with primary cells.
In both academic and pharmaceutical laboratories it is of
advantage to be able to record ion channels in a more physi-
ologically relevant environment, e.g., primary cell cultures, for
drug discovery, biophysical and physiological analysis, and safety
pharmacology using an APC system.
Fast external exchange,minimal compound exposure, and con-
tinuous current recording make the Patchliner and SyncroPatch
96 suited to ligand-gated ion channel measurements. Fast desen-
sitizing receptors such as the nicotinic α7 receptor can be reliably
recorded when taking advantage of the possibility to minimize
the exposure time of the cell to the compound. The applied com-
pound solution, e.g., containing the ligand can be replaced by a
control solution after 200 ms. Volumes of the ligand containing
or control solution and speed of application are set by the user
to control speed of exchange and ligand exposure time. Settings
can be adapted according to the receptor of interest to optimize
reproducibility of current responses.
Providers of APC devices constantly strive to improve and
extend the application range of these devices and features. As
described in this manuscript, recordings in the current clamp
mode and at physiological temperature are relevant features
and will be of good use in the future in both academic and
pharmaceutical research.
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